Bicycle Therapeutics (BCYC) Analyst & Key Data

Analyst Consensus

Buy7 analysts

Buy

Updated Sep 12, 2026

Total Analysts7

Buy

17

Hold

4

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score1.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score5.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$3.86

Median Target+188.60%

$11.14

Potential upside vs current price

Current Stock Price

$3.86

Median Target+188.60%

$11.14

Potential upside vs current price

Analyst Consensus

Buy7 analysts

Buy

Updated Sep 12, 2026

Total Analysts7

Buy

17

Hold

4

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score1.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score5.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$3.86

Median Target+188.60%

$11.14

Potential upside vs current price

Current Stock Price

$3.86

Median Target+188.60%

$11.14

Potential upside vs current price

Bicycle Therapeutics plc